Major US indices surge, with the S&P 500 reaching record highs. Analysts weigh in on market trends, using historical data and technical indicators like the 13/34-week EMA to predict future performance. Despite potential risks, the overall outlook remains bullish.
Tharimmune, Inc. (THAR) stock skyrocketed on Wednesday after the company received positive feedback from the European Medicines Agency (EMA) regarding its TH104 clinical program for treating pruritus in primary biliary cholangitis. This positive news, combined with the company’s commitment to advancing innovative solutions in inflammation and immunology, has investors excited about the future of TH104.
Bayer AG has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for elinzanetant, a potential new treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause. This follows the FDA’s acceptance of Bayer’s marketing application for elinzanetant last week. The EMA submission is based on positive results from the Phase 3 OASIS clinical trials, which demonstrated a statistically significant reduction in the frequency of hot flashes compared to placebo.
Apellis Pharmaceuticals shares plummeted on Friday after the European Medicines Agency (EMA) rejected its drug pegcetacoplan for treating geographic atrophy, a form of age-related macular degeneration. The EMA’s decision comes despite support from the European retina community and dissenting votes from some members of the committee.
The European Medicines Agency (EMA) has recommended a label update for Novo Nordisk’s Wegovy (semaglutide 2.4 mg), incorporating data showing its potential to reduce heart failure symptoms and improve physical function in obese individuals with heart failure with preserved ejection fraction (HFpEF). This update is based on positive results from the STEP HFpEF trials, which demonstrated Wegovy’s efficacy in reducing heart failure symptoms, improving physical limitations, and promoting weight loss compared to placebo.
